We report a case of fatal adriamycin cardiomyopathy in a 12-year-old boy treated for Ewing's sarcoma. At necropsy, in addition to the typical changes of advanced cardiotoxicity in the myocardium there was endocardial fibroelastosis, mainly affecting the left ventricle.
LefrakEAPithaJRosenheimSGottliebJA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer197332:302–314.
2.
WilcoxRGJamesPDToghillPJ. Endomyocardial fibrosis associated with daunorubicin therapy. Br Heart J197638:860–863.
3.
FitterWdeSaDJPaiKRM. Adriamycin cardiotoxicity: Report of an unusual case with features resembling endomyocardial fibrosis. J Clin Pathol198134:602–605.
4.
BillinghamMEMasonJWBristowMRDanielsJR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep197862:865–872.
5.
McKinneyB. Pathology of cardiomyopathies. London: Butterworth & Co. 1974:398–421,11–28.
6.
GilladogaACCorazonMTanCCWollnerNMurphyML. Cardiotoxicity of Adriamycin (NSC-123127) in children. Cancer Chemother Rep19756:209–214.
7.
HermanEMhatreRLeeIPVickJWaravdekarVS. A comparison of the cardiovascular actions of daunomycin, Adriamycin and N-acetyl daunomycin in hamsters and monkeys. Pharmacology19716:230–241.
8.
SellersFJKeithJDManningJA. The diagnosis of primary endocardial fibroelastosis. Circulation196429: 49–59.
9.
KlineIKMillerAJPickRKatzLN. The relationship between human endocardial fibroelastosis and obstruction of the cardiac lymphatics. Circulation196430:728–735.
10.
JaenkeRS. Adriamycin induced myocardial lesions: Report of a workshop. Am J Surg Pathol19771:55–60.
